|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG006059716 |
| 003 |
DE-627 |
| 005 |
20230425181104.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2023 xx |||||o 00| ||und c |
| 035 |
|
|
|a (DE-627)CTG006059716
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2020-000647-30-BG
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EFC16645
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a und
|
| 245 |
1 |
0 |
|a Nonrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (HERCULES)
|b A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis - HERCULES
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 16-06-2020, Last updated: 2023-01-13
|
| 650 |
|
4 |
|a Medical Condition: Non-relapsing Secondary Progressive Multiple Sclerosis MedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 3
|
| 650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 09. Jan.
|
| 773 |
1 |
8 |
|g year:2023
|g day:09
|g month:01
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000647-30
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2023
|b 09
|c 01
|
Klinische Studie